TAXOMET: A French prospective multicenter randomized controlled phase II study comparing docetaxel plus metformin versus docetaxel plus placebo in mCRPC.

Marc Pujalte Martin,Delphine Borchiellini,Julien Viotti,Aline Guillot,Jean Baptiste Paoli,Dominique Besson,Werner Hilgers,Claude El Kouri,Gerard Cavaglione,Frank Priou,Tifenn Lharidon,Rémy Largillier,Jean-Laurent Deville,Benjamin Hoch,Renaud Schiappa,Jean-François Tanti,Frédéric Bost,Jean-Marc Ferrero

TAXOMET: A French prospective multicenter randomized controlled phase II study comparing docetaxel plus metformin versus docetaxel plus placebo in mCRPC.

2019

Marc Pujalte Martin
Delphine Borchiellini
Julien Viotti
Aline Guillot
Jean Baptiste Paoli
Dominique Besson
Werner Hilgers
Claude El Kouri
Gerard Cavaglione
Frank Priou
Tifenn Lharidon
Rémy Largillier
Jean-Laurent Deville
Benjamin Hoch
Renaud Schiappa
Jean-François Tanti
Frédéric Bost
Jean-Marc Ferrero

5004Background: Docetaxel (DOCE) is a standard of care in metastatic castration-resistant prostate cancer (mCRPC). Several retrospective cohort studies suggest a decrease in PC incidence and mortal...

Keywords:

Placebo
Prostate cancer
Physical therapy
Phases of clinical research
Metformin
Oncology
Retrospective cohort study
Docetaxel
Internal medicine
Medicine
standard of care

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations